Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

86.28 +0.50 (+0.58%)
Official Closing Price Updated: 7:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Improving Medical Care in the Black Community With Family Health Histories
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
From Merck & Co., Inc.
Via Business Wire
FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
From Merck & Co., Inc.
Via Business Wire
Employees Help Evacuate Patients From Record Flood in China
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
From Merck & Co., Inc.
Via Business Wire
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
From Merck & Co., Inc.
Via Business Wire
Leslie A. Brun Resigns from Merck Board of Directors
From Merck & Co., Inc.
Via Business Wire
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
Via FinancialNewsMedia
Merck Has Been Named One of the Top Employers in New York by Fortune
SOURCE: Merck & Co., Inc. 
Via 3BL Media
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
From Merck & Co., Inc.
Via Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
Merck Named by Seramount As One of the Best Companies for Multicultural Women
SOURCE: Merck & Co., Inc. 
Via 3BL Media
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
From Merck & Co., Inc.
Via Business Wire
Merck Has Earned the Top Spot on Forbes' 2021 List of 'Best Employers for New Graduates'
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
From Merck & Co., Inc.
Via Business Wire
Merck Announces Second-Quarter 2021 Financial Results
From Merck & Co., Inc.
Via Business Wire
Merck Recognized on Best Places to Work for Disability Inclusion List and Received Perfect Score on the Disability Equality Index (DEI)
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Supply Chain
Merck Announces Fourth-Quarter 2021 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
From Merck & Co., Inc.
Via Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
From Merck & Co., Inc.
Via Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
VERQUVO® (vericiguat) Approved in the European Union
From Merck & Co., Inc.
Via Business Wire
Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021
From Merck & Co., Inc.
Via Business Wire
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC
From Merck & Co., Inc.
Via Business Wire
Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.